Anupam Rasayan India and Mates Visa Consultancy have officially acquired a 50.07% controlling stake in Bliss GVS Pharma. The acquisition, completed on September 28, 2026, involves a combination of a share purchase agreement, on-market buys, and an open offer. The transition marks a formal change in promoter status, with the new entities now holding majority control over the pharmaceutical firm. Investors should watch for upcoming announcements regarding potential changes to board composition and long-term business strategy under the new ownership.
Bliss GVS Pharma Ownership Transition
Acquirer and PAC secure 50.07% stake; assume official promoter status at Bliss GVS Pharma.
Reader Takeaway: New majority owners bring fresh strategic control, shifting the company's long-term management and operational direction.
What just happened
Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have completed their acquisition of Bliss GVS Pharma Ltd. As of September 28, 2026, the entities hold a combined 50.07% stake, officially becoming the company's new promoters. This transition follows a structured process including a share purchase agreement and a regulatory open offer.
Why this matters
The change in control is a significant event for retail shareholders. An ownership shift of this scale often precedes changes in corporate strategy, board representation, and operational focus. The completion of the open offer and compliance with SEBI SAST regulations ensures the transfer has met mandatory transparency requirements.
The backstory
Anupam Rasayan and its partner, Mates Visa Consultancy, utilized a multi-stage acquisition strategy. This included a primary share purchase agreement for 47.95% of equity, supplemented by on-market purchases and the successful conclusion of an open offer, which was previously outlined in disclosures dated July 18, 2026.
Risks to watch
Investors should monitor how the integration with the new promoter group impacts current margins and product development timelines. Sudden changes in management or strategic pivots could influence stock volatility in the near term.
What to track next
Watch for exchange filings regarding new board appointments and any announcements from the incoming promoter group regarding their specific vision for the company's pharmaceutical business.